Hercules Capital, Inc. Common Stock (HTGC) is currently showing a bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: Higher-value headlines lean clearly negative, with stronger signals around downgrades, warnings, weak results, or other pressure points.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
9/100
Bearish
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
High
Headline depth
Last Price
$16.11
Trend Context
Mixed / range
Latest briefing
What's happening with HTGC
globenewswire.com29 Jun 2026
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com23 Jun 2026
Hercules Capital: This 12% Yield Is My Top Pick For The Back Half
Hercules Capital stands out among BDCs for its resilient, venture-focused portfolio and minimal AI disruption risk. HTGC maintains strong credit quality, with only 0.1% of its portfolio on non-accrual and a 12% yield, supporting a Strong Buy rating. Portfolio composition is 44% healthcare/life sciences and 35% application software, with high barriers to entry and AI beneficiaries.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com22 Jun 2026
Hercules Capital Faces Its Own 12 Labors
Hercules Capital is trading at a 30% premium to NAV, down from 72% in 2024, reflecting compressed sentiment around technology-focused BDCs. HTGC is paying out a 12.1% dividend yield, with a $0.40 base and a $0.07 supplemental quarterly dividend. The base dividend was 120% covered by first-quarter net investment income. Portfolio credit quality remains robust, with nonaccruals at fair value at just 0.1% of the total investment portfolio as of the end of the first quarter.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
17 Jun 2026
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
